Schall, Brown & Schwartz LLP

CCOI Investors Face Sept. 21 Deadline in Cogent Fraud Suit

Los Angeles – September 11, 2026 -- Shareholders of Cogent Communications Holdings, Inc. (NASDAQ: CCOI) have until September 21, 2026, to seek lead plaintiff status in a securities fraud class action covering purchases made between February 29, 2024, and May 1, 2026.

Law firm Schall, Brown & Schwartz LLP alleges Cogent misrepresented its optical wavelength order backlog

According to the complaint filed by Schall, Brown & Schwartz LLP ('SBS'), Cogent's stated backlog of orders for optical wavelength products was unlikely to generate revenue because customers in that backlog were unwilling to accept delivery, even where the company was capable of fulfilling orders. The suit alleges the company was not on track to meet its revenue targets and other performance goals throughout the class period, rendering its public statements materially misleading under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

Capricor Therapeutics Faces Securities Fraud Suit Over Deramiocel BLA

Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP (SBS) has issued a reminder to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a securities class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lead plaintiff deadline is set for September 28, 2026.

Lawsuit covers CAPR shares purchased between December 17, 2025 and July 26, 2026

The class action targets investors who purchased Capricor shares during this roughly seven-month window. Appointment as lead plaintiff is not a prerequisite for shareholders to participate in any eventual recovery.

Blaize Holdings Faces Securities Fraud Suit Over Revenue Claims

Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a class action lawsuit against Blaize Holdings, Inc. (NASDAQ: BZAI), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lawsuit covers investors who purchased BZAI shares between July 18, 2025 and April 28, 2026, with a lead plaintiff filing deadline set for October 5, 2026.

Complaint alleges Blaize recognized revenue from entities lacking meaningful business activity

According to the complaint, Blaize created an appearance of growth by announcing transactions with counterparties that were not capable of meaningful business operations. The company then improperly recognized revenue from these arrangements, rendering its public statements throughout the class period false and materially misleading, the filing states.

Schall, Brown & Schwartz Files Securities Fraud Suit Against Beta Bionics

Los Angeles – – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a federal securities class action against Beta Bionics, Inc. (NASDAQ: BBNX), alleging the company misled investors about FDA findings tied to its iLet Bionic Pancreas insulin pump. The case, Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999, is pending in the U.S. District Court for the Central District of California.

Class period spans July 2025 to February 2026 amid disputed FDA findings

The class covers purchasers of Beta Bionics common stock between July 30, 2025 and February 24, 2026. Investors face a November 3, 2026 deadline to seek appointment as lead plaintiff.